Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms 1Melanoma 1Lymphoma 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Depressive Disorder, Major 1Depression 1Biliary Tract Neoplasms 1

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4regorafenib 3Specimen Handling 3Nivolumab 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2pembrolizumab 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2cabozantinib 2Etoposide 2Docetaxel 2tocilizumab 1tazemetostat 1poly ICLC 1palbociclib 1naxitamab 1mifamurtide 1humanized 3F8 anti-GD2 monoclonal antibody 1glucarpidase 1gamma-Glutamyl Hydrolase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Osteosarcoma × Psilocybin × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡